Board summary
Key figures
47,611
Registered population
56.6% aged 18–64
24.3%
Aged 65+
ICB 18.8% · England 17.9%
5.3%
Ethnic minority (non-White)
2.2% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 0.8% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
7,897
Hypertension register
+6.65% in 3 yrs · England +5.60%
405
SMI register
30.8% of Waverley's
641
COPD register
Reviews +1.06% in 3 yrs
Forecast to 2030
9,398
Hypertension patients, 2030
+1,501 on today
68.7%
QRISK ≥20% on statins, 2030
+4.40pp over 3 yrs
6.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Heart failure reviews trail national and ICB averages.
Annual heart failure reviews fell 6.7% over three years (England +8.7%) to 65.7%, below Waverley (67.9%), England (78.5%) and the ICB (79.9%).
High-risk lipid therapy and diabetes statins lag England.
Lipid-lowering therapy in QRISK ≥ 20% is 58.8% (England 63.6%), while statin treatment in diabetes without CVD is 68.3% (England 73.2%).
Asthma review coverage grew faster than national trend.
Asthma annual reviews rose +10.5% over three years (England +4.4%) to 65.7% (England 65.7%), though about 1,100 register patients remain unreviewed.
Population, age and ethnicity
Older adults comprise 24.3% of the PCN list, well above the England average
West of Waverley PCN serves 47,611 registered patients. Patients aged 65+ represent 24.3% of the list (11,583 patients), higher than Waverley (22.0%), NHS Surrey Heartlands Integrated Care Board (18.8%) and England (17.9%). The 18–64 age band accounts for 56.6% (26,966 patients) and aged 0–17 for 19.0% (9,062 patients). Area Census resident data shows 94.7% White (Waverley 93.6%, ICB 85.3%, England 81.1%) and 2.2% Asian / Asian British (Waverley 2.8%, ICB 7.7%, England 9.6%). Census ethnicity reflects usual residents rather than registered patients.
Age profile
65+: ICB 18.8%, England 17.9%
Ethnicity
Older people · falls rows are Waverley local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Waverley LA) | 2,164 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.4% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.6% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Waverley LA) | 912 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Waverley LA) | 9.6 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
West of Waverley records 0.0% Core20 deprivation with an 8.2 average IMD decile
West of Waverley PCN records 0.0% Core20 deprivation, matching Waverley (0.0%), below NHS Surrey Heartlands Integrated Care Board (0.8%) and England (21.0%). Estimated Core20 count is 0 across all four practices, reconciling with the 0.00% weighted practice share. The PCN average IMD decile is 8.2 (Waverley 8.5, NHS Surrey Heartlands Integrated Care Board 7.9, England 5.5), ranging from 7.6 at Witley Surgery and 7.8 at Chiddingfold Surgery to 8.4 at Haslemere Health Centre and Grayshott Surgery. Health inequality initiatives may need to target specific clinical cohorts rather than area deprivation.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
405
SMI register
0.84% recorded prevalence
322
Learning disability register
0.67% recorded prevalence
40
Care homes, 1,536 beds
In the PCN catchment
7.8%
Provide unpaid care
Waverley, Census 2021
The PCN records 322 learning disability patients (0.7% prevalence, above Waverley at 0.5%, NHS Surrey Heartlands Integrated Care Board at 0.5% and England at 0.6%) and 405 severe mental illness patients (0.8% prevalence). Catchment care homes total 40 with 1,536 beds. At borough level, Waverley recorded a 7.8% unpaid care rate and 4 rough sleepers in autumn 2025.
Severe mental illness: physical health checks
SMI recorded prevalence is 0.8%. Blood pressure checks reached 83.2% (England 83.4%) and BMI recording was 80.3% (England 82.1%), trailing at Witley Surgery (72.7% BP; 71.2% BMI). This gap may reflect separate recall workflows, which local audits could test.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,897
Hypertension register
+6.65%
Register growth, 3 yrs
Waverley +6.01% · England +5.60%
−1.32pp
BP control, under 80
≤140/90 · +1.39pp aged 80+
+1,501
More patients by 2030
Forecast 9,398 (18.67%)
Hypertension case-finding and control
Recorded hypertension prevalence is 16.4% (7,897 patients), above Waverley (15.4%), England (15.2%) and NHS Surrey Heartlands ICB (14.3%). Under-80 blood pressure control fell 1.9% over three years to 67.2% (England +3.2%, ICB +3.8%). Similarly, annual reviews for 671 heart failure patients (1.4% prevalence) fell 6.7% over three years to 65.7% (England +8.7% to 78.5%). Slower progress despite high prevalence may reflect review capacity constraints, unverified locally. Control and review rates lag national trends despite high recorded prevalence, indicating an operational need to prioritise structured clinical recalls.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reached 58.8%, below England (63.6%) and the ICB (59.4%). Statin coverage for diabetes patients without cardiovascular disease was 68.3%, trailing England (73.2%). Fewer at-risk patients receive lipid-lowering therapy than national benchmarks imply, indicating an opportunity to prioritise systematic primary-prevention statin recalls.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 98,811 | £1.70 | £2.24 | £1.86 | £167,979 |
| Cardiovascular (all), 2025 | 124,455 | £4.09 | £4.74 | £3.33 | £509,021 |
In 2026, the PCN prescribed 98,811 lipid-regulating items at £1.70 per item, below England (£1.86) and NHS Surrey Heartlands ICB (£2.24). The PCN spent £15,810 less than at England's unit cost and £53,358 less than the ICB's. With unit costs below national and ICB levels, clinical priorities should focus on treatment reach rather than prescribing expenditure.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+10.47%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.53%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.0% (3,204 patients; England 6.6%). Annual reviews rose +10.5% over three years (England +4.4%) to 65.7% (matching England 65.7%), leaving about 1,100 patients unreviewed. For asthma patients aged 6-19, second-hand smoke recording reached 75.5% (252 patients; England 78.8%). Meanwhile, COPD prevalence is 1.3% (641 patients; England 1.9%), and annual reviews trail at 74.1% (England 76.4%). Prioritising unreviewed asthma cases and COPD reviews could support timely care.
Cancer register and children's immunisation
Cancer prevalence is 5.5% (2,632 patients; England 3.8%). Childhood immunisation remains strong, with MMR dose 2 at age 5 reaching 95.4% (England 82.8%). However, the 4-in-1 pre-school booster is 94.4% (below the 95.0% target by 0.6 pp), and Grayshott Surgery records a 9.1 pp difference between first (95.5%) and second (86.4%) doses at age five. Timely follow-up may help reduce pre-school coverage gaps.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
61.4%
Surrey Heartlands ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~650
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Surrey Heartlands ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 65.7% | 53.2% | 18% | 1,044 |
| Breast | 88.2% | 85.4% | 27% | 798 |
| Bowel | 48.1% | 47.0% | 18% | 626 |
| Lung | 33.2% | 33.8% | 17% | 497 |
| Skin cancer | 89.8% | 87.8% | 19% | 384 |
In 2022, 61.4% of cancers with a known stage across NHS Surrey Heartlands ICB were diagnosed at stage 1 or 2 (2,955 of 4,810 staged cancers; 67.7% known-stage coverage across 7,106 registered cancers), 13.6 pp below the 75.0% ambition by 2028 (England 55.3%). Closing this ICB gap requires about 650 additional early-stage diagnoses annually. Stage data reflects the wider ICB system, not PCN performance. Locally, PCN cervical screening uptake is 72.1% (England 66.8%, Waverley 73.8%), falling 0.4% from 2023 to 2025 (England -1.0%, Waverley +1.5%), ranging from 69.0% at Witley Surgery and 69.3% at Grayshott Surgery to 78.8% at Chiddingfold Surgery.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional July 2026 data, Royal Surrey NHS Foundation Trust achieved 82.6% on the 28-day faster diagnosis standard (7.6 pp above the 75.0% standard; England 79.3%, NHS Surrey and Sussex ICB 79.3%). On 62-day referral to treatment, Royal Surrey reached 84.5% (0.5 pp below the 85.0% standard; England 71.2%, ICB 71.5%). In July 2026 diagnostics, Royal Surrey recorded 0.0% waiting 6+ weeks for Colonoscopy and Magnetic Resonance Imaging, but 49.7% for Audiology - Audiology Assessments. Provider waits describe the wider system, not PCN performance.
| Pathways within standard (%) | Royal Surrey | Frimley Health | Sussex | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 82.62 | 87.95 | 74.01 | 79.29 | 79.32 |
| 31-day treatment (96%) | 96.43 | 92.89 | 76.79 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 84.48 | 81.84 | 65.20 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Royal Surrey | Frimley Health | Sussex | England |
|---|---|---|---|---|
| MRI | 0.00 | 12.85 | 5.62 | 21.40 |
| CT | 0.15 | 0.63 | 8.57 | 9.92 |
| Echocardiography | 1.55 | 3.35 | 0.39 | 28.48 |
| Colonoscopy | 0.00 | 22.84 | 39.35 | 30.83 |
| Gastroscopy | 0.00 | 7.43 | 20.02 | 29.02 |
| All 15 DM01 tests | 8.82 | 7.49 | 12.95 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In provisional June 2026 community services data, adults aged 65 and over accounted for 69.6% of community contacts among Waverley borough residents (76,215 of 109,530 contacts). These borough-level figures describe the wider system and are not captured at PCN level.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Chiddingfold | 87 | 0.0 | 97.7% | 75.7% | 96.6% |
| Witley Surgery | 110 | 0.0 | 79.7% | 62.5% | 93.4% |
| Haslemere | 94 | 0.0 | 63.6% | 75.7% | 92.8% |
| Grayshott Surgery | 106 | 0.0 | 74.6% | 70.9% | 89.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eleven tracked measures trail England's three-year trend, led by heart failure reviews
Eleven of 25 tracked indicators trail England's three-year trajectory. Heart failure reviews fell 6.7% over three years (England +8.7%), leaving current review coverage at 65.7% compared to 78.5% nationally. Non-frail diabetes HbA1c control (<= 58 mmol/mol) fell 1.1% (England +4.4%), although current achievement is 58.6% (England 57.4%). Conversely, strengths include asthma reviews, which grew 10.5% (England +4.4%), and psychosis alcohol recording, which rose 10.4 pp (England +5.4 pp). These diverging trends may reflect uneven clinical review capacity across conditions; local appointment audits would test this.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Diabetes HbA1c control
BP control, under 80
Breast screening (53-70)
Hypertension BP reading
Asthma reviews
Alcohol record (psychosis)
Diabetes statin (CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Waverley | Asset | PCN | Waverley |
|---|---|---|---|---|---|
| Care homes (catchment) | 40 (1,536 beds) | n/a | Schools (catchment) | 59 | n/a |
| Children's centres | 1 | 7 | Places of worship | 60 | 95 |
| Libraries | n/a | 4 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | n/a | 2 | Children and young people (VCS) | n/a | 1 |
| Carers support groups (VCS) | n/a | 1 | Primary schools (LA maintained) | 12 | 18 |
| Primary academies | 6 | 17 | Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Cardiovascular recall and therapy escalation
QRISK ≥ 20% lipid therapy is 58.8% (England 63.6%), under-80 BP control fell 1.9% to 67.2% (England +3.2% to 67.8%), and heart failure reviews fell 6.7% to 65.7% (England 78.5%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Combined SMI physical health check recall
Across 405 SMI patients (0.8% prevalence; 30.8% of Waverley's register), BMI recording is 80.3% (England 82.1%) and BP checks are 83.2% (England 83.4%), with Witley Surgery at 72.7% BP and 71.2% BMI. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Structured asthma and COPD review recall
Asthma reviews cover 65.7% of 3,204 patients (England 65.7%), leaving 1,099 (about 1,100) unreviewed; COPD reviews reach 74.1% of 641 patients (England 76.4%), with an unadjusted register gap up to 261. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult care coordination (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| SMI physical health check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Under-eighty blood pressure control audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall audit (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Cardiovascular recall and therapy escalation (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Combined SMI physical health check recall (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN & Practice |
| Option 3 · Structured asthma and COPD review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
